NCT05278208 - Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 21, 2022

Primary Completion Date

November 30, 2027

Study Completion Date

November 30, 2027

Conditions

High Grade GliomaMeningiomaEmbryonal TumorMedulloblastomaAnaplastic EpendymomaRecurrent Diffuse Intrinsic Pontine GliomaRecurrent Malignant GliomaRecurrent MedulloblastomaRecurrent Primary Central Nervous System NeoplasmRefractory Diffuse Intrinsic Pontine GliomaRefractory Malignant GliomaRefractory MedulloblastomaRefractory Primary Central Nervous System Neoplasm

Interventions

DRUG

LUTATHERA® (Lutetium Lu 177 dotatate)

Lutathera: IV administration maximum dose of 200 mCi once every 8 weeks (one cycle) for total of 4 cycles (8 months)

Trial Locations (4)

19104

NOT_YET_RECRUITING

Children's Hospital of Philadelphia, Philadelphia

43235

RECRUITING

Nationwide Children's Hospital, Columbus

45229

RECRUITING

Cincinnati Children's Hospital Medical Center, Cincinnati

80045

WITHDRAWN

Children's Hospital Colorado, Aurora

All Listed Sponsors

lead

Nationwide Children's Hospital

OTHER